SEC 10-Q Summary — Quarter Ended March 31, 2020
Entity discrepancy: The request identifies Gyre Therapeutics, Inc., but the supplied 10-Q is for Catalyst Biosciences, Inc. (NASDAQ: CBIO). Confirm that this is the intended filing.
Business context and reporting period
Catalyst is a clinical-stage biopharmaceutical company developing engineered protease candidates in hemostasis and complement regulation. It had no approved products and no product-sales revenue. The unaudited results cover the three months ended March 31, 2020, compared with the same period in 2019.
Financial results and liquidity
- Revenue: $16.4 million, versus none in Q1 2019, principally the $15.0 million upfront Biogen license payment plus $1.3 million of collaboration revenue.
- Revenue-related costs: $4.5 million ($3.0 million license cost and $1.4 million collaboration cost). The implied remainder after these costs was about $11.9 million, or 72.6% of revenue; this is a calculated measure, not a reported gross-profit subtotal.
- Expenses and earnings: R&D expense was $13.3 million, up 10%; G&A was $3.7 million, essentially unchanged. Operating loss was $5.1 million versus $15.7 million; net loss was $4.1 million versus $15.1 million. Loss per share was $0.28 versus $1.26.
- Cash flow: Operating cash use was $4.8 million, compared with $15.0 million. Investing activities provided $27.4 million, largely from investment maturities; financing provided $32.4 million, primarily from the February stock offering. Cash and cash equivalents increased by $55.0 million.
- Liquidity and debt: Cash, cash equivalents and short-term investments totaled $104.5 million at quarter-end, including $70.4 million of cash and equivalents. Total liabilities were $13.0 million, including operating lease liabilities; the filing reports no borrowings. Management said available resources were expected to fund requirements for at least 12 months from the filing date.
- Other balance-sheet measures: Total assets were $110.6 million; stockholders’ equity was $97.5 million; accumulated deficit was $262.6 million.
Material changes versus Q1 2019
- Biogen collaboration revenue drove the change from no revenue to $16.4 million. The agreement licenses anti-C3 candidates for potential AMD and other indications; Biogen funds specified research services and is responsible for later clinical development and commercialization.
- Net loss narrowed by $11.0 million, despite a $5.7 million increase in total operating expenses, mainly because of license and collaboration revenue. R&D increased by $1.2 million, primarily from preclinical spending.
- The company raised approximately $32.0 million net in a February public offering of 5.3 million shares at $6.50 per share, increasing shares outstanding.
Outlook, risks and contingencies
- Management expected losses to continue for several years and R&D spending to increase as MarzAA, DalcA and anti-complement programs advance. No specific revenue or earnings guidance was provided.
- Management planned to initiate a MarzAA Phase 3 trial in 2020, subject to COVID-19-related delays; expected final DalcA Phase 2b data in Q2 2020; and expected gene-therapy nonhuman-primate data in Q2 2020. These were forward-looking expectations, not reported outcomes.
- COVID-19 could delay trial enrollment, site activation, data analysis, research, manufacturing and supply logistics, and could raise costs or complicate future financing. The company said the pandemic’s full effect was uncertain.
- Manufacturing commitments included $3.4 million remaining under AGC work orders and $0.4 million under Catalent work orders. The company also disclosed $1.7 million of operating lease liabilities and potential milestone or royalty payments under license agreements.
- Subsequent event: On May 8, 2020, Catalyst amended its Mosaic agreement to replace certain percentage-based payment obligations with a $0.75 million payment and up to $4.0 million in future milestones. Catalyst said it would retain all future payment streams for the specified candidates.
- The company stated it had no material legal proceedings and no off-balance-sheet arrangements. It warned that future financing might not be available on acceptable terms; additional equity could dilute shareholders.
Most important facts for investors to verify
- Confirm the filing entity: the supplied document is Catalyst Biosciences, not Gyre Therapeutics.
- Review the Biogen agreement’s milestone, royalty, termination and research-cost terms, and the accounting behind the Q1 upfront license revenue.
- Check subsequent clinical-trial progress and whether COVID-19 affected the stated 2020 milestones, trial timelines or manufacturing plans.
- Assess cash burn against the stated 12-month runway, outstanding manufacturing commitments, and any financing or dilution since the filing.
- Review the May 8 Mosaic amendment and related-party approval disclosures, including the remaining milestone obligations.